Medscape (5/29, Brooks, Subscription Publication) reported, “Treatment with the antidepressant bupropion does not improve apathy in nondepressed patients with dementia of Alzheimer type,” researchers concluded in a 108-patient, “multicenter, double-blind, placebo-controlled trial,” investigators found. Even though the medication is “safe in this patient population, bupropion was no better than placebo in reducing apathy, neuropsychiatric symptoms, or health-related quality of life, the researchers say.” The findings were published online May 28 in JAMA Network Open